A A A

Alimera Sciences Announces 9 Clinical Presentations and a Sponsored Symposium at 17th Euretina Congress

Alimera Sciences Announces 9 Clinical Presentations and a Sponsored Symposium at 17th Euretina Congress

Sep 5, 2017
20 electronic posters available for review as well

ATLANTA, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in commercialization and development of prescription ophthalmic pharmaceuticals, today announced that data from 7 ILUVIEN® post marketing studies involving 1,586 eyes to be presented during the 17th European Society of Retina Specialists Congress (EURETINA), September 7-10, 2017, in Barcelona. Seven presentations will be given by speakers from the podium, while there will be 20 electronic posters that will be available throughout the meeting for review by EURETINA attendees and available on the EURETINA website following the meeting. Additionally, two presentations will be given on the effects of a fluocinolone implant on posterior uveitis.

On Friday, September 8, Alimera will sponsor a symposium as part of the EuroTimes Satellite Education Program. Entitled "Continuous Microdosing with ILUVIEN®: Real-world Optimisation of the Treatment of Chronic DME," the lunchtime event will be moderated by Hans Hoerauf from the Department of Ophthalmology, University of Goetingen, Germany and Borja Corcóstegui from the Institut Microcirurgia Ocular, Barcelona, Spain.

Panel participants include: Anat Loewenstein from Department of Ophthalmology, Tel Aviv Medical Center, and the Sackler Faculty of Medicine, Tel Aviv University, Israel; Francisco Goñi from Centro de Tratamiento Integral del Glaucoma – Centro Médico Teknon, Barcelona, Spain; and, Bernardete Pessoa from Hospital de Santo Antonio, Porto, Portugal.

The scheduled times, titles and locations of the nine speaker presentations are as follows:

  • U. Chakravarthy, S. Taylor, C. Bailey, F. Koch, J. Souza UK
    ILUVIEN® (190 micrograms fluocinolone acetonide) real-life safety and effectiveness following usage in three European countries – results from the 2016 extract of data from the ILUVIEN® Registry Safety, Thursday, September 7, 9:18 a.m., Room 117 (Level 1).

  • A. Augustin GERMANY
    Results from the RETRO-IDEAL study assessing the real-world ILUVIEN® (fluocinolone acetonide) outcomes in patients with chronic diabetic macular edema (DME) up to 3 years after therapy was initiated, Thursday, September 7, 2:30 p.m., Room 117 (Level 1).

  • C. Currie, S. Holden, D. Owens UK
    Evaluation of the clinical effectiveness in routine practice of the fluocinolone acetonide intravitreal implant in patients with diabetic macular edema, Thursday, September 7, 2:48 p.m., Room 117 (Level 1).

  • L. Weber, S. Marx, G. Auffarth, S. Sel, A. Scheuerle, T. Tandogan, R. Khoramnia GERMANY
    Fluocinolone acetonide intravitreal implant for treatment of non-infectious uveitic macular edema, Friday, September 8, 12:06 p.m., Room 111 (Level 1). 

  • C. Pavesio UK
    An injectable fluocinolone acetonide intravitreal insert in patients with chronic non-infectious uveitis affecting the posterior segment of the eye: Effects on macular edema at 6 months, Friday, September 8, 12:18 p.m., Room 111 (Level 1).

  • J. Coelho, B. Pessoa, A. Abreu, N. Correia, N. Ferreira, J. Melo Beirao, A. Meireles PORTUGAL
    Efficacy and safety of fluocinolone acetonide implant in vitrectomised and non-vitrectomized eyes for treatment of chronic diabetic macular edema, Saturday, September 9, 3:30 p.m., Room 120 (Level 1).

  • M. Rehak, M. Tuisl, C. Jochmann, P. Wiedemann GERMANY
    Fluocinolone acetonide intravitreal implant for treatment of diabetic macular edema. Long term real life results, Saturday, September 9, 5:18 p.m., Room 120 (Level 1).

  • A. Meireles, C. Teixeira, J. Castro e Sousa, M. Falcao, J. Coelho, R. Goncalves, B. Pessoa PORTUGAL
    Report of 12 months efficacy and safety of ILUVIEN® (0.2 μg/d fluocinolone acetonide [FAC]) for chronic diabetic macular edema in Portugal, Sunday, September 10, 8:42 a.m., Room 120 (Level 1).

  • D. Sahota, H. Ibrahim, R. Sivaraj UK
    Identifying patients appropriate for treatment with fluocinolone acetonide (ILUVIEN®). When do we switch from anti-VEGF in diabetic macular edema? A retrospective audit in a UK single-center setting, Sunday, September 10, 11:06 a.m., Room 117 (Level 1).

About ILUVIEN

U.S. website www.ILUVIEN.com

ILUVIEN'S U.S. Indication

ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is a sustained release intravitreal implant approved in the U.S. to treat diabetic macular edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. Each ILUVIEN implant is designed to release submicrogram levels of fluocinolone acetonide, a corticosteroid, for 36 months.

ILUVIEN'S E.U. Indication

ILUVIEN is indicated for the treatment of vision impairment associated with chronic diabetic macular oedema, considered insufficiently responsive to available therapies.

About Diabetic Macular Edema (DME)

DME, the primary cause of vision loss associated with diabetic retinopathy, is a disease affecting the macula, the part of the retina responsible for central vision. When the blood vessel leakage associated with diabetic retinopathy results in swelling of the macula, the condition is called DME. The onset of DME is painless and may go unreported by the patient until it manifests with the blurring of central vision or acute vision loss. The severity of this blurring may range from mild to profound loss of vision. The Wisconsin Epidemiologic Study of Diabetic Retinopathy found that over a 10-year period approximately 19% of people with diabetes included in the study were diagnosed with DME. All people with type 1 or type 2 diabetes are at risk of developing DME.

About Alimera Sciences, Inc.

www.alimerasciences.com

Alimera Sciences (NASDAQ:ALIM), founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera’s commitment to retina specialists and their patients is manifest in Alimera’s product and development portfolio designed to treat early- and late-stage diseases. For more information, please visit www.alimerasciences.com.

For press inquiries:
Katie Brazel
for Alimera Sciences
404-317-8361
kbrazel@bellsouth.net

For investor inquiries:
CG Capital
for Alimera Sciences
877-889-1972
investorrelations@cg.capital

Primary Logo

Alimera Sciences, Inc.